CA2484217A1 - Muscarinic antagonists - Google Patents

Muscarinic antagonists Download PDF

Info

Publication number
CA2484217A1
CA2484217A1 CA002484217A CA2484217A CA2484217A1 CA 2484217 A1 CA2484217 A1 CA 2484217A1 CA 002484217 A CA002484217 A CA 002484217A CA 2484217 A CA2484217 A CA 2484217A CA 2484217 A1 CA2484217 A1 CA 2484217A1
Authority
CA
Canada
Prior art keywords
alkyl
group
compound
compound according
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002484217A
Other languages
English (en)
French (fr)
Inventor
Craig D. Boyle
William J. Greenlee
Samuel Chackalamannil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2484217A1 publication Critical patent/CA2484217A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002484217A 2002-04-26 2003-04-24 Muscarinic antagonists Abandoned CA2484217A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37609302P 2002-04-26 2002-04-26
US60/376,093 2002-04-26
PCT/US2003/012694 WO2003091220A1 (en) 2002-04-26 2003-04-24 Muscarinic antagonists

Publications (1)

Publication Number Publication Date
CA2484217A1 true CA2484217A1 (en) 2003-11-06

Family

ID=29270760

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002484217A Abandoned CA2484217A1 (en) 2002-04-26 2003-04-24 Muscarinic antagonists

Country Status (11)

Country Link
US (1) US6890936B2 (enExample)
EP (1) EP1499596B1 (enExample)
JP (2) JP4527408B2 (enExample)
CN (1) CN1649845A (enExample)
AT (1) ATE413388T1 (enExample)
AU (1) AU2003228674A1 (enExample)
CA (1) CA2484217A1 (enExample)
DE (1) DE60324544D1 (enExample)
ES (1) ES2315494T3 (enExample)
MX (1) MXPA04010552A (enExample)
WO (1) WO2003091220A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
AU2005287037A1 (en) * 2004-09-20 2006-03-30 Targacept, Inc. Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
EP2275096A3 (en) * 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
WO2008039863A2 (en) * 2006-09-27 2008-04-03 Braincells, Inc. Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2011143457A2 (en) 2010-05-12 2011-11-17 Northwestern University Compositions and methods for treating or preventing atrial fibrillation
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2964103C (en) * 2014-10-31 2022-08-30 Indivior Uk Limited Dopamine d3 receptor antagonist compounds
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
EP3651762B1 (en) 2017-07-12 2024-07-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3732163A4 (en) * 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04225953A (ja) * 1990-05-07 1992-08-14 Shionogi & Co Ltd スピロ　ジベンゾスベラン誘導体
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
AU2206699A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives

Also Published As

Publication number Publication date
MXPA04010552A (es) 2005-01-25
JP2010059213A (ja) 2010-03-18
US6890936B2 (en) 2005-05-10
EP1499596B1 (en) 2008-11-05
US20040067972A1 (en) 2004-04-08
DE60324544D1 (de) 2008-12-18
JP4527408B2 (ja) 2010-08-18
HK1068136A1 (en) 2005-04-22
CN1649845A (zh) 2005-08-03
ES2315494T3 (es) 2009-04-01
EP1499596A1 (en) 2005-01-26
JP2006507220A (ja) 2006-03-02
ATE413388T1 (de) 2008-11-15
AU2003228674A1 (en) 2003-11-10
WO2003091220A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
EP1499596B1 (en) Muscarinic antagonists
EP1370528B1 (en) Mch antagonists and their use in the treatment of obesity
US6472394B1 (en) MCH antagonists and their use in the treatment of obesity
AU2002350269B2 (en) Piperidine -based MCH antagonists for treatment of obesity and CNS disorders
NZ530429A (en) Substituted urea neuropeptide Y Y5 receptor antagonists
EP1434766B1 (en) Piperidine compounds as muscarinic antagonists
EP3526203B1 (en) N-aryl and n-heteroaryl piperidine derivatives as liver x receptor beta agonists, compositions, and their use
NZ552059A (en) Piperidine derivatives as NK1 antagonists
AU2002348269A1 (en) N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
CA2490470A1 (en) Pyrazole urea neuropeptide y y5 receptor antagonists
WO2004002987A1 (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
EP1601664B1 (en) Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
US7345042B2 (en) MCH antagonists for the treatment of obesity
EP1902044A1 (en) 5-htx modulators
WO2006035280A1 (en) 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
HK1068136B (en) Muscarinic antagonists
AU2002244308A1 (en) MCH antagonists and their use in the treatment of obesity
HK1056877B (en) Mch antagonists and their use in the treatment of obesity
HK1071567B (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued